Business Context and Reporting Period
Company: SeaStar Medical Holding Corp (Nasdaq: ICU)
Filing Type: Form 8-K (Current Report)
Report Date: January 28, 2025
Subject: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (Item 3.01). The filing addresses a public reprimand from Nasdaq regarding a potential violation of Listing Rule 5635(d) concerning shareholder approval for equity issuances.
Key Financial Metrics
This filing is a regulatory notice and does not contain financial statements, revenue, profit, cash flow, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes and Regulatory Action
- Nasdaq Reprimand: On January 28, 2025, the Company received a public reprimand letter from Nasdaq staff regarding a violation of Listing Rule 5635(d).
- Violation Details: The violation stemmed from amendments to a 2023 transaction involving convertible notes and warrants. These amendments resulted in the issuance of approximately 625,722 shares beyond the originally approved amount, plus an additional 288,832 shares issued upon exercise of warrants at prices below the minimum floor price.
- Remedial Actions Taken:
- The Company repurchased all remaining Additional Warrants for cash; no Additional Warrants remain outstanding.
- The balance under the Convertible Notes is fully paid; no notes remain outstanding.
- Stockholders ratified the Transaction, Amendments, and Additional Warrants at a special meeting on November 26, 2024.
- Outcome: Nasdaq determined that delisting was not an appropriate sanction. The review was closed with the issuance of the public reprimand. The Company's Common Stock remains listed on Nasdaq.
Guidance, Outlook, and Risks
Management Commentary: Management stated that at the time of the issuance and adjustments, the Company believed the entire transaction had been approved by shareholders. The receipt of the reprimand letter has no effect on the listing status of the Common Stock.
Risks and Contingencies: The primary risk addressed was the potential delisting due to the equity issuance violation. This risk has been mitigated by the Nasdaq decision to issue a reprimand rather than delist the stock.
Key Facts for Investor Verification
- Verify that the Company's stock (ICU) remains actively listed on The Nasdaq Stock Market LLC.
- Confirm that no Additional Warrants or Convertible Notes remain outstanding following the buyback and repayment.
- Review the minutes or proxy statement from the special stockholder meeting held on November 26, 2024, to confirm the ratification of the disputed transaction.
- Monitor future filings for any additional correspondence from Nasdaq regarding compliance with Listing Rule 5635(d).